Sierra Leone is one of the highest malaria burden countries
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Introduction
A cross-sectional study conducted in 2017 1 involving 68 primary health facilities in Koinadugu district of rural Sierra Leone compared the management of children with fever for malaria for a period before, during and after the Ebola outbreak. There were two key findings. First, less than half of all confirmed malaria cases were treated for malaria during the Ebola outbreak. As fever is a common symptom of both malaria and Ebola, health workers may have "played safe" by simply referring such children to Ebola management sites 2 . Second, monthly utilization of malaria diagnostics closely matched the number of reported fever cases, implying that fever cases were being routinely subjected to malaria testing 3 .
Although the post-Ebola period was included in this evaluation, it was for a relatively short period (six months) which was probably too soon to gauge health system recovery. At the primary healthcare level in the same district and among children under five, we thus performed a new analysis with a longer post-Ebola period and compared these data for similar periods before and during the Ebola outbreak. Our specific objectives were to determine: a) numbers of reported fever cases and malaria tests done, and b) numbers treated for malaria with artemisinin combination treatment (ACT) and within 24 hours of fever onset
Methods
This was a cross-sectional study using routine program data. The setting has been previously described 1 . The study population included all children under five with fever who presented to 68 primary healthcare units. Malaria management was in line with national guidelines and has been described previously 4 . In brief, all individuals presenting with fever to any given health facility were subjected to a malaria diagnostic test, which may involve a Rapid Diagnostic Test (RDT) or microscopy. Only confirmed malaria cases should receive ACT.
The study spanned a pre-Ebola (June 1 2013 -April 30 2014 Table 1 shows the numbers of fever cases reported and malaria tests done during the pre-, intra-and post-Ebola periods (see underlying data 5 ). Fever cases increased from 43,245 pre-Ebola to 74,367 post-Ebola (1.7-fold increase). Diagnosed malaria among fever cases ranged between 66% and 75%. During Ebola, all diagnosed malaria cases had malaria tests, while in the pre-and post-Ebola periods, 99% received testing and 1% was diagnosed on clinical grounds.
Results

Numbers of reported fever cases and malaria tests done
Numbers treated for malaria in relation to ACT and fever onsets Table 2 shows numbers treated for malaria in relation to ACT and timing of fever onset. While all diagnosed malaria cases received treatment in the pre-and post-Ebola periods, only 47% were treated during Ebola. ACT use was 95% pre-Ebola, 99% intra-Ebola and dropped to 71% post-Ebola. In the post-Ebola period, out of 68 health facilities, an average of 7.5 facilities per month had 7 days stockouts of ACT.
Discussion
This study shows that despite the Ebola outbreak, the number of reported fever cases progressively increased and was 1.7 times higher post-Ebola compared to the pre-Ebola period.
Reassuringly, while less than half of malaria cases received treatment with ACT drugs during Ebola, in the post-Ebola period, all cases received treatment (which included ACT and other anti-malarial drugs). ACT use declined from 99% during Ebola to 71% post-Ebola, and this was accompanied with ACT stock-outs. This could be explained by the increase in numbers needed to be treated for malaria in the post-Ebola period (2.8-times that during Ebola), which might have caused pressure on available ACT stocks and supply chains.
As part of Sierra Leone's post-Ebola health recovery strategy 6 , more health personnel were trained in surveillance and reporting, incentives were introduced, and community involvement was promoted. Operationally, this seems to have increased health service utilisation for malaria, but the health system seemed unable to cope with the increased ACT demand. This needs to be addressed in order to ensure compliance with malaria treatment guidelines and the rational use of antimalarial drugs.
The main study strength is that we used data from all health facilities in the district and compared similar periods of time before, during and after the Ebola outbreak. A study limitation was the lack of data on complicated and uncomplicated malaria cases. Availability of such information would help to justify (or not) the use of other antimalarial drugs apart from ACT which was seen in the post-Ebola period. A short-coming in the district health information system (DHIS2) is that it does not capture severity of malaria (complicated and uncomplicated malaria). Adding this variable would improve monitoring of rational use of antimalarials.
In conclusion, what has changed since the Ebola outbreak is the increased utilisation of services for malaria. However, ACT stockouts are of concern, and this requires attention in order to ensure compliance with national malaria treatment guidelines. 
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The authors used recent references to synthesize the research gap and the generation of new knowledge. However, scientifically strong justification is essential to clarify why the existing records needed a comparative analysis (pre, intra and post Ebola periods). Please include why this research is necessary.
The study design used is appropriate in addressing the research question.
Sufficient details of the methods used were noted except the list of variables used for analyses. The authors can improve the methods section by adding the type of variables extracted from the morbidity register so as to allow replication by others.
For the analysis, in Table 1 , the percentages of total cases diagnosed as malaria either by RDT or microscopy out of all fever cases are to be included and interpreted carefully. "Diagnosed malaria among fever cases ranged between 66% and 75%" is not enough. In fact, in post Ebola period, diagnosed malaria among fever cases was lower than pre and intra Ebola outbreak period (66%). This indicates less need for diagnostics despite increased utilization of health services for children with fever.
In Table 2 , during Ebola period, cases treated for malaria dropped to 47% which should be included in the discussion part.
Conclusion part is weak and needs to rewrite and add what needs to be done further.
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